Wang Pan, Zhang Chaoqi, Wu Peng, Zhao Zhihong, Sun Nan, Xue Qi, Gao Shugeng, He Jie
Department of Thoracic Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
MedComm (2020). 2025 May 29;6(6):e70237. doi: 10.1002/mco2.70237. eCollection 2025 Jun.
The exploration of cell death and cellular senescence (CDS) in cancer has been an area of interest, yet a systematic evaluation of CDS features and their interactions in lung adenocarcinoma (LUAD) to understand tumor heterogeneity, tumor microenvironment (TME) characteristics, and patient clinical outcomes is previously uncharted. Our study characterized the activities and interconnections of 21 CDS features in 1788 LUAD cases across 15 cohorts, employing unsupervised clustering to categorize patients into three CDS subtypes with distinct TME profiles. The CDS index (CDSI), derived from principal component analysis, was developed to assess individual tumor CDS regulation patterns. Twelve CDSI core genes, enriched in proliferating T cells within the TME as per single-cell analysis, were identified and their functional roles and prognostic significance were validated. High CDSI correlated with improved overall survival in discovery cohort, four independent validation cohorts, and subgroup analysis. CDSI-low patients exhibited a favorable clinical response to immunotherapy and potential sensitivity to mitosis pathway drugs, while CDSI-high patients might benefit from drugs targeting ERK/MAPK and MDM2-p53 pathways. The clinical utility of CDSI was further validated using 9185 pan-cancer samples, demonstrating the broad relevance of our prediction model across various cancer types and its potential clinical implications for cancer management.
癌症中细胞死亡与细胞衰老(CDS)的探索一直是一个备受关注的领域,然而,此前尚未有人对肺腺癌(LUAD)中CDS特征及其相互作用进行系统评估,以了解肿瘤异质性、肿瘤微环境(TME)特征和患者临床结局。我们的研究对15个队列中1788例LUAD病例的21种CDS特征的活性和相互联系进行了表征,采用无监督聚类将患者分为三种具有不同TME特征的CDS亚型。通过主成分分析得出的CDS指数(CDSI)用于评估个体肿瘤的CDS调控模式。通过单细胞分析,我们鉴定出12个CDSI核心基因,这些基因在TME中的增殖T细胞中富集,并验证了它们的功能作用和预后意义。在发现队列、四个独立验证队列和亚组分析中,高CDSI与总体生存率的提高相关。CDSI低的患者对免疫治疗表现出良好的临床反应,对有丝分裂途径药物具有潜在敏感性,而CDSI高的患者可能从靶向ERK/MAPK和MDM2-p53途径的药物中获益。使用9185个泛癌样本进一步验证了CDSI的临床实用性,证明了我们的预测模型在各种癌症类型中的广泛相关性及其对癌症管理的潜在临床意义。